Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
2020/10/01 by A. Wollenberg, Andreas Wollenberg, A. Blauvelt +39 · 36 citations
Medicine · Immunology and Microbiology · #Dermatology and Skin Diseases #Allergic Rhinitis and Sensitization #Psoriasis: Treatment and Pathogenesis
paper · pdf · doi:10.1111/bjd.19574
Abstract
BACKGROUND: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements in AD signs and symptoms. OBJECTIVES: To evaluate the efficacy and safety of tralokinumab monotherapy in adults with moderate-to-severe AD who had an inadequate response to topical treatments. METHODS: In two 52-week, randomized, double-blind, placebo-controlled, phase III trials, ECZTRA 1 and ECZTRA 2, adults with moderate-to-severe AD were randomized (3 : 1) to subcutaneous tralokinumab 300 mg every 2 weeks (Q2W) or placebo. Primary endpoints were Investigator's Global Assessment (IGA) score of 0 or 1 at week 16 and ≥ 75% improvement in Eczema Area and Severity Index (EASI 75) at week 16. Patients achieving an IGA score of 0 or 1 and/or EASI 75 with tralokinumab at week 16 were rerandomized to tralokinumab Q2W or every 4 weeks or placebo, for 36 weeks. The trials were registered with ClinicalTrials.gov: NCT03131648 and NCT03160885. RESULTS: At week 16, more patients who received tralokinumab vs. placebo achieved an IGA score of 0 or 1: 15·8% vs. 7·1% in ECZTRA 1 [difference 8·6%, 95% confidence interval (CI) 4·1-13·1; P = 0·002] and 22·2% vs. 10·9% in ECZTRA 2 (11·1%, 95% CI 5·8-16·4; P < 0·001) and EASI 75: 25·0% vs. 12·7% (12·1%, 95% CI 6·5-17·7; P < 0·001) and 33·2% vs. 11·4% (21·6%, 95% CI 15·8-27·3; P < 0·001). Early improvements in pruritus, sleep interference, Dermatology Life Quality Index, SCORing Atopic Dermatitis and Patient-Oriented Eczema Measure were observed from the first postbaseline measurements. The majority of week 16 tralokinumab responders maintained response at week 52 with continued tralokinumab treatment without any rescue medication (including topical corticosteroids). Adverse events were reported in 76·4% and 61·5% of patients receiving tralokinumab in ECZTRA 1 and ECZTRA 2, respectively, and in 77·0% and 66·0% of patients receiving placebo in ECZTRA 1 and ECZTRA 2, respectively, in the 16-week initial period. CONCLUSIONS: Tralokinumab monotherapy was superior to placebo at 16 weeks of treatment and was well tolerated up to 52 weeks of treatment.
Citations
Cited by
- Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*
- Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
- Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
- The role of OX40 ligand/OX40 axis signalling in atopic dermatitis
- Adriforant is a functional antagonist of histamine receptor 4 and attenuates itch and skin inflammation in mice
- Engineering the IL‐4/IL‐13 axis for targeted immune modulation
- Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial
- European Guideline on Chronic Pruritus. In cooperation with the European Dermatology Forum (EDF)
- Triggers, Drivers, and Lids: Uncovering the Mechanistic Differentiators between IL-4– and IL-13–Targeted mAbs
- Systemic therapies for atopic dermatitis
- Biologic Therapies Targeting Type 2 Signaling in Atopic Dermatitis: A Comparative Review of Structural and Thermodynamic Differences in Mechanism of Action
- Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. [europepmc]
- Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies. [europepmc]
- Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. [europepmc]
- Antibodies to watch in 2021. [europepmc]
- Itch in Atopic Dermatitis - What Is New? [europepmc]
- Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis. [europepmc]
- Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis. [europepmc]
- Gut Microbiota, Probiotics, and Their Interactions in Prevention and Treatment of Atopic Dermatitis: A Review. [europepmc]
- Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. [europepmc]
- Skin barrier defects in atopic dermatitis: From old idea to new opportunity. [europepmc]
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. [europepmc]
- Manipulating Microbiota to Treat Atopic Dermatitis: Functions and Therapies. [europepmc]
- Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis. [europepmc]
- Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. [europepmc]
- Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. [europepmc]
- Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives. [europepmc]
- The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. [europepmc]
- Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations. [europepmc]
- Overview of Atopic Dermatitis in Different Ethnic Groups. [europepmc]
- Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. [europepmc]
- Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases. [europepmc]
- Therapeutic Antibodies in Medicine. [europepmc]
- Genetic and Immunological Pathogenesis of Atopic Dermatitis. [europepmc]
- Sensory neurons promote immune homeostasis in the lung. [europepmc]
- Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update. [europepmc]
Related